SCHEMBL23326425

SCHEMBL23326425

CN(C)c1ccc(Nc2nc(NN)nc(N3CCOCC3)n2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.61
LMNA P02545 3/20 0.61
SMN1; SMN2 Q16637 2/20 0.61
CYP1A2 P05177 1/20 0.61
CYP3A4 P08684 1/20 0.61
CYP2C9 P11712 1/20 0.61
CYP2C19 P33261 1/20 0.61
KMT2A Q03164 2/20 0.57
MEN1 O00255 1/20 0.57
HTT P42858 2/20 0.56
MCL1 Q07820 1/20 0.55
CA12 O43570 2/20 0.55
CA1 P00915 2/20 0.55
CA2 P00918 2/20 0.55
CA9 Q16790 2/20 0.55
PTGS2 P35354 2/20 0.55
GAA P10253 2/20 0.53
TAAR1 Q96RJ0 1/20 0.53
POLB P06746 2/20 0.53
TP53 P04637 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23321396 0.86 LMNA (0.82) MAPTLMNASMN1; SMN2CYP1A2CYP3A4
SCHEMBL23326278 0.85 PTGS2 (0.61) MAPTLMNASMN1; SMN2CYP1A2CYP3A4
SCHEMBL1657522 0.84 MAPT (0.87) MAPTLMNASMN1; SMN2CYP1A2CYP3A4
SCHEMBL29583869 0.84 MAPT (0.87) MAPTLMNASMN1; SMN2CYP1A2CYP3A4
SCHEMBL14735692 0.84 GBA1 (0.69) MAPTLMNASMN1; SMN2CYP1A2CYP3A4
SCHEMBL14735802 0.83 LMNA (0.81) MAPTLMNASMN1; SMN2CYP1A2CYP3A4
SCHEMBL11812589 0.79 LMNA (0.94) MAPTLMNASMN1; SMN2CYP1A2CYP3A4
SCHEMBL11615257 0.78 LMNA (0.66) MAPTLMNASMN1; SMN2CYP1A2CYP3A4
SCHEMBL8908286 0.78 CTSS (0.72) MAPTLMNASMN1; SMN2CYP1A2CYP3A4
SCHEMBL22737374 0.77 MAPT (0.62) MAPTLMNASMN1; SMN2CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240368184-A1 PIKfyve Inhibitors MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2024-11-07 US disclosed
US-12030896-B2 PIKfyve inhibitors MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2024-07-09 US disclosed
US-12030896-B2 PIKfyve inhibitors MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2024-07-09 US disclosed
US-12030896-B2 PIKfyve inhibitors MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2024-07-09 US disclosed
US-20210139505-A1 PIKfyve Inhibitors Sanford Burnham Prebys Medical Discovery Institute 2021-05-13 US disclosed
US-20210139505-A1 PIKfyve Inhibitors Sanford Burnham Prebys Medical Discovery Institute 2021-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12030896-B2 PIKfyve inhibitors PIKFYVE, PIP4K2B, PIP4K2A MAPT 3914/4885LMNA 3750/4885SMN1; SMN2 2618/4885
US-20210139505-A1 PIKfyve Inhibitors PIKFYVE, PIP4K2B, PIP4K2A MAPT 3914/4885LMNA 3750/4885SMN1; SMN2 2618/4885
US-20240368184-A1 PIKfyve Inhibitors PIKFYVE, PIP4K2B, PIP4K2A MAPT 3914/4885LMNA 3750/4885SMN1; SMN2 2618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.